Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
AFT Leaves X Over AI-Generated Images of Minors 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
LOS ANGELES, March 30, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq:RGLS) concerning possible violations of federal securities laws between January 21, 2016 and June 27, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the April 3, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Regulus made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. On June 27, 2016, the Company announced that it received notice from the U.S. Food and Drug Administration (“FDA”) that its new drug for the treatment of chronic hepatitis C virus infection which was under FDA review, is now being put on clinical hold after a second serious case of jaundice was reported. When this information was released, the stock price of Regulus fell, causing investors harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
